United States flu vaccine Market Report by Price Trade, Market Trade, Import and Export, Growth, Supply and Demand Forecast 2017-2022.
United States flu vaccine Market from Qurates Repository provides detailed information, in depth analysis and forecast which is developed by team of experts and professionals.
(EMAILWIRE.COM, September 11, 2018 ) United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-DPI-HnM-3136
Longterm Growth Projection and Development:
Sanofi to Acquire Protein Sciences Corporation
It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine
The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.
Purchase Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-DPI-HnM-3136/ (Priced at USD 1150)
Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024 provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an indepth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
Key Topics Covered in the Report
Market Overview: United States Flu Vaccine Market (2010 - 2024)
United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
Reimbursement & Regulatory System in the US Flu Vaccine Market
Mergers, Acquisitions, Key Agreements & Collaborations
Promising Flu Vaccine in Clinical Development
Flu Vaccine Clinical Trial Insights by Phase, Company & Country
Key Drivers and Inhibitors of the US Flu Vaccine Market
Key Companies Analysis
Major Flu Vaccines Covered Under This Report Are:
Fluzone HighDose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-DPI-HnM-3136
Table of Content:
1. Executive Summary
2. Market Overview: United States Flu Vaccine Market (2010 - 2024)
3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
4. Key Drivers and Inhibitors of the United States Flu Vaccine Market
4.1 Market Drivers
4.2 Market Inhibitors
5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
5.1 Flu Vaccine Price Trends
6. United States Flu Vaccine Market Reimbursement & Regulatory System
6.1 Reimbursement System
6.2 Regulation System
7. Market Dynamics Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
8. Flu Vaccine Promising Vaccine in Clinical Development
8.1 Quadrivalent Seasonal Influenza VLP Vaccine
9. Flu Vaccine Clinical Trial Insights by Phase, Company & Country
9.1 Year 2017
9.2 Year 2016
10. Key Companies Analysis
Enquiry for Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-DPI-HnM-3136
List of figures: List of Tables
Table 52: United States Pediatric Flu Vaccine Price, 2017 2018
Table 53: United States Adult Flu Vaccine Price, 2017 2018
Table 54: United States Flu Vaccine Production, Supply, and Allocation
Table 55: Total Percentage of Flu Vaccines Released by Week,2016 2017
Table 56: Total Percentage of Flu Vaccines Released by Week,2015 2016
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-DPI-HnM-3136
Longterm Growth Projection and Development:
Sanofi to Acquire Protein Sciences Corporation
It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine
The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.
Purchase Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-DPI-HnM-3136/ (Priced at USD 1150)
Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024 provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an indepth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
Key Topics Covered in the Report
Market Overview: United States Flu Vaccine Market (2010 - 2024)
United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
Reimbursement & Regulatory System in the US Flu Vaccine Market
Mergers, Acquisitions, Key Agreements & Collaborations
Promising Flu Vaccine in Clinical Development
Flu Vaccine Clinical Trial Insights by Phase, Company & Country
Key Drivers and Inhibitors of the US Flu Vaccine Market
Key Companies Analysis
Major Flu Vaccines Covered Under This Report Are:
Fluzone HighDose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-DPI-HnM-3136
Table of Content:
1. Executive Summary
2. Market Overview: United States Flu Vaccine Market (2010 - 2024)
3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
4. Key Drivers and Inhibitors of the United States Flu Vaccine Market
4.1 Market Drivers
4.2 Market Inhibitors
5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
5.1 Flu Vaccine Price Trends
6. United States Flu Vaccine Market Reimbursement & Regulatory System
6.1 Reimbursement System
6.2 Regulation System
7. Market Dynamics Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
8. Flu Vaccine Promising Vaccine in Clinical Development
8.1 Quadrivalent Seasonal Influenza VLP Vaccine
9. Flu Vaccine Clinical Trial Insights by Phase, Company & Country
9.1 Year 2017
9.2 Year 2016
10. Key Companies Analysis
Enquiry for Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-DPI-HnM-3136
List of figures: List of Tables
Table 52: United States Pediatric Flu Vaccine Price, 2017 2018
Table 53: United States Adult Flu Vaccine Price, 2017 2018
Table 54: United States Flu Vaccine Production, Supply, and Allocation
Table 55: Total Percentage of Flu Vaccines Released by Week,2016 2017
Table 56: Total Percentage of Flu Vaccines Released by Week,2015 2016
Contact Information:
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Qurate Business Intelligence
Nehal Chinoy
Tel: +919881074592
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results